Data and maps
WHO promotes the dissemination and sharing of health data, including surveillance and epidemiological data. WHO also produces a regular global report on HIV drug resistance (HIVDR) threats, prevalence and trends, which is based on information shared by countries.
Countries are encouraged to ensure prompt interpretation and dissemination of HIVDR data at a national level and to WHO for timely public health assessment. This informs national and global policies, allows a coordinated response to be implemented, and helps advocate for action on HIVDR prevention and response.
Reports
HIV drug resistance – brief report 2024
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV...
HIV drug resistance report 2021
HIV drug resistance (HIVDR) can compromise the effectiveness of antiretroviral therapy (ART) in reducing HIV incidence and HIV-associated morbidity and...
HIV drug resistance report 2019
The rise in antimicrobial resistance (AMR) is one of the greatest threats to global health. If it is not urgently addressed, it may result in millions...
HIV drug resistance report 2017
This second HIV drug resistance (HIVDR) report provides an update on recent population levels of HIVDR covering the period 2014–2016. The report...
With increasing global use of antiretroviral therapy (ART) to both treat and prevent HIV, and increasing global trends in HIV drug resistance (HIVDR),...
HIV drug resistance report 2012
This report assesses the general levels of transmitted and acquired drug resistance in select geographical areas of low- and middle-income countries. It...
Maps
Implementation of acquired HIV drug resistance surveys among adults receiving dolutegravir-based antiretroviral therapy with viral load ≥1000 copies/ml, 2019-2023
As of July 2023, only 10 countries had finalised the implementation of acquired HIV drug resistance surveys among adults receiving dolutegravir-based antiretroviral therapy with viral load ≥1000 copies/mL; three surveys are ongoing, and 24 surveys are planned.
Implementation of acquired HIV drug resistance surveys among children and adolescents receiving dolutegravir-based antiretroviral therapy with viral load ≥1000 copies/ml, 2019-2023
As of July 2023, only six countries had implemented surveys of acquired HIV drug resistance among children and adolescents receiving dolutegravir-based antiretroviral therapy with unsuppressed viral load; one survey is ongoing, and 14 surveys are planned.
